Logo image of ALCLS.PA

CELLECTIS (ALCLS.PA) Stock Price, Quote, News and Overview

EPA:ALCLS - Euronext Paris - Matif - FR0010425595 - Common Stock - Currency: EUR

1.288  -0.02 (-1.68%)

ALCLS.PA Quote, Performance and Key Statistics

CELLECTIS

EPA:ALCLS (6/6/2025, 7:00:00 PM)

1.288

-0.02 (-1.68%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.33
52 Week Low1.01
Market Cap129.17M
Shares100.29M
Float52.38M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04
IPO02-06 2007-02-06


ALCLS.PA short term performance overview.The bars show the price performance of ALCLS.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

ALCLS.PA long term performance overview.The bars show the price performance of ALCLS.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of ALCLS.PA is 1.288 EUR. In the past month the price decreased by -7.34%. In the past year, price decreased by -45.42%.

CELLECTIS / ALCLS Daily stock chart

ALCLS.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.51 294.28B
AMG.DE AMGEN INC 13.9 135.93B
1AMGN.MI AMGEN INC 13.85 135.48B
GIS.DE GILEAD SCIENCES INC 14.44 121.78B
1GILD.MI GILEAD SCIENCES INC 14.14 119.24B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 100.95B
ARGX.BR ARGENX SE 109.81 31.45B
22UA.DE BIONTECH SE-ADR N/A 23.10B
IDP.DE BIOGEN INC 8.4 17.06B
0QF.DE MODERNA INC N/A 9.33B
1MRNA.MI MODERNA INC N/A 9.10B
BIO.DE BIOTEST AG N/A 1.67B

About ALCLS.PA

Company Profile

ALCLS logo image Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

Company Info

CELLECTIS

8, rue de la Croix Jarry

Paris ILE-DE-FRANCE FR

Employees: 219

ALCLS Company Website

ALCLS Investor Relations

Phone: 33181691600

CELLECTIS / ALCLS.PA FAQ

What is the stock price of CELLECTIS today?

The current stock price of ALCLS.PA is 1.288 EUR. The price decreased by -1.68% in the last trading session.


What is the ticker symbol for CELLECTIS stock?

The exchange symbol of CELLECTIS is ALCLS and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALCLS.PA stock listed?

ALCLS.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for CELLECTIS stock?

14 analysts have analysed ALCLS.PA and the average price target is 6.63 EUR. This implies a price increase of 414.75% is expected in the next year compared to the current price of 1.288. Check the CELLECTIS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CELLECTIS worth?

CELLECTIS (ALCLS.PA) has a market capitalization of 129.17M EUR. This makes ALCLS.PA a Micro Cap stock.


How many employees does CELLECTIS have?

CELLECTIS (ALCLS.PA) currently has 219 employees.


What are the support and resistance levels for CELLECTIS (ALCLS.PA) stock?

CELLECTIS (ALCLS.PA) has a support level at 1.12 and a resistance level at 1.33. Check the full technical report for a detailed analysis of ALCLS.PA support and resistance levels.


Is CELLECTIS (ALCLS.PA) expected to grow?

The Revenue of CELLECTIS (ALCLS.PA) is expected to grow by 63.01% in the next year. Check the estimates tab for more information on the ALCLS.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CELLECTIS (ALCLS.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CELLECTIS (ALCLS.PA) stock pay dividends?

ALCLS.PA does not pay a dividend.


When does CELLECTIS (ALCLS.PA) report earnings?

CELLECTIS (ALCLS.PA) will report earnings on 2025-08-04.


What is the Price/Earnings (PE) ratio of CELLECTIS (ALCLS.PA)?

CELLECTIS (ALCLS.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.53).


ALCLS.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALCLS.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALCLS.PA. While ALCLS.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALCLS.PA Financial Highlights

Over the last trailing twelve months ALCLS.PA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS increased by 45.54% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -14.12%
ROE -41.34%
Debt/Equity 0.65
Chartmill High Growth Momentum
EPS Q2Q%-325%
Sales Q2Q%85.12%
EPS 1Y (TTM)45.54%
Revenue 1Y (TTM)357.43%

ALCLS.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to ALCLS.PA. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of -235.09% and a revenue growth 63.01% for ALCLS.PA


Ownership
Inst Owners20.91%
Ins Owners3.88%
Short Float %N/A
Short RatioN/A
Analysts
Analysts85.71
Price Target6.63 (414.75%)
EPS Next Y-235.09%
Revenue Next Year63.01%